GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Total Current Liabilities

VRCDF (Verici Dx) Total Current Liabilities : $2.04 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Verici Dx's total current liabilities for the quarter that ended in Dec. 2024 was $2.04

Verici Dx Total Current Liabilities Historical Data

The historical data trend for Verici Dx's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Total Current Liabilities Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Liabilities
0.68 1.80 2.25 3.51 2.04

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only 2.25 2.20 3.51 1.97 2.04

Verici Dx Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Verici Dx's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.701+0.182
+Other Current Liabilities+Current Deferred Liabilities
=1.155+0
=2.04

Verici Dx's Total Current Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.701+0.182
+Other Current Liabilities+Current Deferred Liabilities
=1.155+0
=2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Verici Dx Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Verici Dx's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Total Current Liabilities
Comparable Companies
LSE:GENI LSE:OBD LSE:GDR LSE:PRM LSE:ABDX TSE:2397 TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA LH WAT DGX XPAR:BIM ILMN
Traded in Other Exchanges
VRCI:UK 63V:Germany
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Website
https://www.vericidx.com
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines